Intravenous Thyroxine for Heart-Eligible Organ Donors

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This randomized controlled trial will evaluate whether intravenous thyroxine infusion given to brain-dead organ donors who are eligible to donate hearts for 12 hours will result in more hearts transplanted than saline placebo

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Washington University School of Medicine
• Collaborator: Mid-America Transplant

Criteria

Inclusion Criteria:

• Declared dead by neurologic criteria (brain dead)

• Authorization for organ donation and research

• On one or more vasopressors and/or inotropes

Exclusion Criteria:

• Brain death declared more than 24 hours prior

• Only vasopressor is vasopressin

• Weight < 45 kg (100 lbs)

• Known coronary artery disease or history of myocardial infarction

• Known valvular heart disease

• Prior sternotomy or cardiac surgery

• Donor at VA hospital

• Received intravenous or oral thyroxine within past month

• Known HIV+ status

• Other reason donor is unable to receive study drug (determined by on-site personnel)